Lyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer

Future Oncology

Volumn 7, Issue 8, 2011, Pages 937-945

  Poon, Ronnie T P ^a   Borys, Nicholas ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Celsion Corp   (United States)

Author keywords

hepatocellular carcinoma; lyso thermosensitive liposomal doxorubicin; radiofrequency ablation

Indexed keywords

DOXORUBICIN; LYSO THERMOSENSITIVE LIPOSOMAL DOXORUBICIN; SORAFENIB; THERMODOX; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BLADDER SPASM; BODY WEIGHT; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSGEUSIA; DYSPNEA; FATIGUE; HEATING; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY INFECTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; LETHARGY; LEUKOPENIA; LIMB PAIN; LIVER CELL CARCINOMA; LIVER DISEASE; LYMPHOCYTOPENIA; MALAISE; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SIDE EFFECT; SORE THROAT; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 80051741377     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.73     Document Type: Article

References (49)

1. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).
2. Mulier S, Mulier P, Ni Y et al. Complications of radiofrequency coagulation of liver tumours. Br. J. Surg. 89, 1206-1222 (2002). (Pubitemid 36002536)
3. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 243, 321-328 (2006). (Pubitemid 43327762)
4. Huang J, Yan L, Cheng Z et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann. Surg. 252, 903-912 (2010).
5. Lin SM, Lin CJ, Lin CC et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percuteanous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54, 1151-1156 (2005).
6. Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J. Surg. 29, 1364-1373 (2005). (Pubitemid 41712667)
7. Ng KK, Poon RT, Lo CM et al. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J. Gastrointest. Surg. 12, 183-191 (2008).
8. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol 1. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).
9. Vivarelli M, Guglielmi A, Ruzzenente A et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann. Surg. 240, 102-107 (2004). (Pubitemid 38808241)
10. Chen MS, Zhang YJ, Li JQ et al. Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 27, 623-625 (2005).
11. Mulier S, Ni Y, Jamart J et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann. Surg. 242, 158-171 (2005). (Pubitemid 41033431)
12. Nerenstone SR, Inde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat. Rev. 15, 1-31 (1988).
13. Lai CL, Wu PC, Chan GC et al. Doxorubicin vs. no antitumor therapy in an inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 62, 479-483 (1988).
14. Yeo W, Mok TS, Zee B et al. A randomized Phase III study of doxorubicin versus cisplatin/interferon a-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97, 1532-1538 (2005). (Pubitemid 41631953)
15. Gish RG, Porta C, Lazar L et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25, 3069-3075 (2007).
16. Needham D, Ponce A. Nanoscale drug delivery vehicles for solid tumors: a new paradigm for localized drug delivery using temperature sensitive liposomes. In:Nanotechnology for Cancer Therapy Amiji M (Ed.). CRC Press, FL, USA, 677-720 (2006).
17. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13, 248-260 (2008). (Pubitemid 351679900)
18. Kong G, Braun R, Dewhirst M. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60, 4440-4445 (2000). (Pubitemid 32103623)
19. Kong G, Braun R, Dewhirst MW. Characterisation of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 61, 3027-3032 (2001). (Pubitemid 32691950)
20. Bates DA, Mackillop WJ. Hyperthermia, adriamycin transport, and cytotoxicity in drug-sensitive and -resistant Chinese hamster ovary cells. Cancer Res. 46, 5477-5481 (1986). (Pubitemid 17177930)
21. Calabro A, Singletary SE, Tucker S et al. In vitro thermo- chemosensitivity screening of spontaneous human tumors: significant potentiation for cisplatin but not adriamycin. Int. J. Cancer 43, 385-390 (1989). (Pubitemid 19092316)
22. Hayashi S, Kano E, Tsuji K et al. Modification of thermosensitivity and chemosensitivity induced by combined treatments with hyperthermia and adriamycin. Int. J. Mol. Med. 8, 417-422 (2001).
23. Herman TS. Temperature dependence of adriamycin, cis- diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res. 43, 517-520 (1983). (Pubitemid 13193840)
24. Herman TS, Sweets CC, White DM, Gerner EW. Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs. J. Natl Cancer Inst. 68, 487-491 (1982). (Pubitemid 12156688)
25. Istomin YP, Zhavrid EA, Alexandrova EN et al. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp. Oncol. 30, 56-59 (2008). (Pubitemid 351518105)
26. Nagaoka S, Kawasaki S, Sasaki K, Nakanishi T. Intracellular uptake, retention and cytotoxic effect of adriamycin combined with hyperthermia in vitro. Jpn J. Cancer Res. 77, 205-211 (1986). (Pubitemid 16138117)
27. Nitta M, Hisazumi H, Nakajima K. Combined cell killing effects of anticancer drugs and hyperthermia in vitro. Hinyokika Kiyo 34, 1525-1528 (1988).
28. Uchibayashi T, Lee SW, Hisazumi H et al. Studies of combined treatment of radiofrequency hyperthermia with anticancer agents or irradiation for invasive bladder cancer. Hinyokika Kiyo 39, 1209-1213 (1993).
29. Uchibayashi T, Lee SW, Kunimi K et al. Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique. Cancer Chemother. Pharmacol. 35(Suppl.) S84-S87 (1994). (Pubitemid 24357249)
30. Urano M, Begley J, Reynolds R. Interaction between adriamycin cytotoxicity and hyperthermia: growth-phase-dependent thermal sensitization. Int. J. Hyperthermia 10, 817-826 (1994). (Pubitemid 24352989)
31. Yoshida M. Effect of adriamycin combined with 40 and 43 degrees C hyperthermia on cultured V79 cells and S-180 tumor and their uptake of the drug. Nippon Igaku Hoshasen Gakkai Zasshi 51, 1098-1104 (1991).
32. Lin SM. Recent advances in radiofrequency ablation in the treatment of hepatocellular carcinoma and metastatic liver cancers. Chang Gung Med. J. 32, 22-32 (2009).
33. Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver 4(Suppl. 1), S113-S118 (2010).
34. Rhim H, Lim HK, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. World J. Gastrointest. Surg. 2, 128-136 (2010).
35. Choi D, Lim HK, Rhim H. Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas. World J. Gastrointest. Surg. 2, 137-142 (2010).
36. Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: current status. World J. Radiol. 2, 417-424 (2010).
37. Morimoto M, Numata K, Kondou M et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116, 5452-5460 (2010).
38. Wang YB, Chen MH, Yan K et al. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual. Life Res. 16, 389-397 (2007). (Pubitemid 46363693)
39. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv. Ther. 25, 787-794 (2008).
40. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-a prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J. Viral Hepat. 17, 287-292 (2010).
41. Hagihara H, Nouso K, Kobayashi Y et al. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int. J. Clin. Oncol. 16(3), 210-220 (2011).
42. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31, 461-476 (2010).
43. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 78(Suppl. 1), 113-124 (2010).
44. Porta C, Paglino C. Medical treatment of unresectable hepatocellular carcinoma: going beyond sorafenib. World J. Hepatol. 2, 103-113 (2010).
45. Chu KJ, Lai EC, Yao XP. Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation - a systematic review and meta-analysis. Asian J. Surg. 33, 120-126 (2010).
46. Thomas MB, Jaffe D, Choti MM et al. Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 28, 3994-4005 (2010).
47. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin. Pharmacother. 10, 333-343 (2009).
48. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Ass. 53, 457-481 (1958).
49. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer 35, 1-39 (1977). (Pubitemid 8018922)